Particle Sciences, a leading drug development CRO, will share formulation, analytic and production responsibilities in an effort to develop a vaginally administered microbicide, a product specifically designed to prevent the sexual transmission of HIV. According to Robert Lee, VP Pharmaceutical Development at Particle Sciences, "Particle Sciences is well qualified for this challenge having extensive expertise in mucosal formulation and previous experience with similar products. We have been developing vaginal gels and sustained delivery systems such as intravaginal rings for some time now and are thrilled to be able to leverage that experience on behalf of Combined Highly Active Anti-retroviral Microbicides program (CHAARM)". According to Charles Kelly of King's College London, CHAARM's coordinator, "We are very pleased to be working with Particle Sciences. Their unique expertise in formulation of compounds for mucosal application will be essential to the success of the program."
"It's a real honor to be able to work on such projects with such a distinguished international team and we are deeply appreciative of the funding provided by the European Commission for this work," said Lee.